Skip to content

Treatment of Depressive Symptoms using Virtual Reality (FlowVR) in Patients with Depression

Treatment of Depressive Symptoms using Virtual Reality (FlowVR) in Patients with Depression - FlowVR

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00029757
Enrollment
50
Registered
2022-07-29
Start date
2022-09-08
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F32 F33 F34

Interventions

Group 1: Interventional = FlowVR, 8 sessions (45 min), 2x per week (intervention period 4 weeks). Each session is structured in the same way. The participant goes individually in a group of three into

Sponsors

Universitätsklinikum Hamburg-EppendorfKlinik für Psychiatrie und PsychotherapieStation für Angst- und Zwangsstörungen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Diagnosis of depression The desire for treatment A (day care) inpatient treatment Consent to participate in FlowVR Ability to give consent Sufficient understanding of the German language

Exclusion criteria

Exclusion criteria: current Psychotic or bipolar disorder Acute suicidality

Design outcomes

Primary

MeasureTime frame
Before-and-after-session-questionnaire: Before and after each session of FlowVR participants receive a before-and-after-questionnaire (adapted version of Miegel et al., [2020]). This questionnaire assesses symptoms, sense of coherence, self-worth, self-efficacy, drive for activity and group cohesion (three items each).

Secondary

MeasureTime frame
Positive Affect Negative Affect Schedule-Expanded Form (PANAS-X): PANAS-X is a self-report measure that assesses positive and negative affect (before and after each session). Subjective Appraisal Questionnaire: This self-report questionnaire assesses subjective appraisal of FlowVR (t1). The questionnaire is based on Jelinek, Zielke et al., (2018). Flow Short Scale (FSS): The FSS assesses state flow in virtual reality (before and after each session). Hamilton-Depressions-Skala: The Hamilton-Depression Scale is an established instrument that assesses depressive symptom severity (t0, t2) Beck Depression Inventory (BDI-II): The BDI-II is a self-report instrument that assesses the severity of depression (t0, t1, t2). Simulator Sickness Questionnaire (SSQ): SSQ is a self-report questionnaire that assesses level of sickness (e.g.) while being in virtual reality (before and after each session). Igroup Presence Questionnaire (IPQ): The IPQ is a self-report questionnaire that assesses sense of presence in virtual reality from a patient point of view (t1). Quality of life – global item (WHO-QOL-BREF): The global item of the self-report questionnaire assesses quality of life (t0, t1, t2). Side effects: The questionnaire assesses side effects of therapy (t1). Rosenberg Self-Esteem Scale (RSES): The RSES is a self-report questionnaire that assesses self-esteem (t0, t1, t2). Metacognitions Questionnaire (MCQ-30): The 30-item questionnaire assesses dysfunctional metacognitive beliefs according to Wells´ model (t0, t2). Global Assessment of Functioning (GAF): GAF is a self-report instrument that assesses the overall level of functioning of a person (t0, t1, t2). State-Trait-Anxiety-Depression-Inventory (STADI): STADI is a self-report questionnaire that assesses anxiety and depression at a state level in a person (in session, before and after each session). Generalized Anxiety Disorder 7 (GAD-7): GAD-7 is a self-report questionnaire that assesses anxiety, which is used a

Countries

Germany

Contacts

Public ContactLuzie Lohse

Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Arbeitsgruppe Klinische Neuropsychologie

lu.lohse@uke.de+49 40 7410 55868

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026